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Abstract
Background: Farmers have an increased risk for musculoskeletal disorders (MSD) such as osteoarthritis of the hip,
low back pain, and neck and upper limb complaints. The underlying mechanisms are not fully understood. Work-
related exposures and inflammatory responses might be involved. Our objective was to identify plasma proteins
that differentiated farmers with MSD from rural referents.
Methods: Plasma samples from 13 farmers with MSD and rural referents were included in the investigation. Gel
based proteomics was used for protein analysis and proteins that differed significantly between the groups were
identified by mass spectrometry.
Results: In total, 15 proteins differed significantly between the groups. The levels of leucine-rich alpha-2-glycoprotein,
haptoglobin, complement factor B, serotransferrin, one isoform of kininogen, one isoform of alpha-1-antitrypsin, and
two isoforms of hemopexin were higher in farmers with MSD than in referents. On the other hand, the levels of
alpha-2-HS-glycoprotein, alpha-1B-glycoprotein, vitamin D- binding protein, apolipoprotein A1, antithrombin, one
isoform of kininogen, and one isoform of alpha-1-antitrypsin were lower in farmers than in referents. Many of the
identified proteins are known to be involved in inflammation.
Conclusions: Farmers with MSD had altered plasma levels of protein biomarkers compared to the referents, indicating
that farmers with MSD may be subject to a more systemic inflammation. It is possible that the identified differences of
proteins may give clues to the biochemical changes occurring during the development and progression of MSD in
farmers, and that one or several of these protein biomarkers might eventually be used to identify and prevent
work-related MSD.
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Background
Farmers in industrialized countries have low morbidity
in general and common disease entities as cancer and
cardiovascular disorders are less frequent among farmers
than in the general population [1]. By contrast, farmers
have an increased risk of acquiring musculoskeletal
disorders (MSD), such as osteoarthritis of the hip, low
back pain, and neck and upper limb complaints [1–3].
The reason for this is not known. We have previously
demonstrated that the increased risk cannot be fully ex-
plained by known risk factors such as physical work
load, psychosocial factors, or life style, indicating that
other etiological factors must be involved. [2–4]. Inter-
estingly, the prevalence of low back pain in farmers is
associated not only with other musculoskeletal symp-
toms but also with chest discomfort, dyspepsia, symp-
toms from eyes, nose and throat mucous membranes,
skin problems, work-related fever attacks, and primary
care appointments due to digestive disorders [4]. This
comorbidity points to the possibility that MSD in
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farmers may be part of a more systemic disorder with
pathological changes in many organs and tissues. Since
blood is in direct contact with all tissues, such changes
are likely to be reflected in plasma [5] and quantitative
changes in the plasma could thus serve as biomarkers of
systemic effects. Moreover, plasma samples are readily
available for investigation, thus making analysis of
plasma a favorable alternative for examining laboratory
signs of a systemic disorder. In a recent study serum
samples from patient with discogenic chronic low back
pain (DLBP) were analyzed by mass spectrometry to
identify biomarkers for DLBP [6].
In this study, our objective was to identify plasma pro-
teins that might differentiate farmers with MSD from
matched rural referents. We focused on relatively abun-
dant plasma proteins which can be quantified to the
nanogram range using two-dimensional gel electrophor-
esis (2DE) with silver staining and subsequent identifica-
tion by mass spectrometry (MS).
Methods
Subjects
The investigated subjects were selected from a prospect-
ive study cohort established with the intention to study
health promoting factors related to farming and lifestyle
[7]. All occupationally active male farmers born between
1930 and 1949 in nine rural municipalities in Sweden
were identified in the Swedish National Farm Register
and included in the cohort. The cohort represents a var-
iety of farm types and geographical variation. The areas
were chosen with consideration to known east-west and
north-south cardiovascular disease gradients in the
Swedish population [8] and to represent a variety of
farm types and geographical variation over the country.
Farmers were defined as men who owned or rented a
farm and who spent at least 25 h per week farming. The
occupational activity was checked with local representa-
tives from the Federation of Swedish Farmers. To each
farmer a rural referent, matched by age, sex and residen-
tial area, was sampled from the National Population
Register. The rural referents were to be occupationally
active in other than farming. Altogether 1220 farmers
and 1130 rural non-farmers were eligible and included
in the cohort. The farmers and the rural referents (n =
2350) were invited to an extensive health survey includ-
ing questionnaires, interviews, physical examinations
and laboratory test [9].
The cross-sectional population-based survey identified
farmers with MSD using a questionnaire with a number
of items addressing symptoms from back, hip, knee,
neck, forearms and shoulders. Information on symptoms
from the musculoskeletal system was assessed by self-
administrated questionnaire [3]. The subjects were asked
to indicate (yes or no) if they had ever (more than
occasionally) had pain, aches or discomfort in the neck-
shoulder area, the low back, hips or knees. The ques-
tionnaire file shows this in more detail (see Additional
file 1). Similar symptoms during the last year were also
indicated. The subjects were asked to indicate whether
they had sought medical advice or treatment for the
various symptoms, and concerning low back and knee
symptoms, whether they had been on sick leave due to
the illness. A large number of farmers and non-farmers
(89 %) reported symptoms from musculoskeletal system.
The farmers reported significantly more symptoms from
low back and hips [4, 9].
This large material was used to identify farmers with
symptoms from the musculoskeletal system only. Thir-
teen farmers working with swine confinement and cattle
raising and their rural referents (Table 1) were selected
and included in this explorative hypothesis generated
study.
Sample preparation
All samples were blinded before analysis. Plasma from
farmers and referents were prepared at the same time
and not separately. 50 μl of plasma was applied onto an
albumin & IgG Depletion column (GE Healthcare). Al-
bumin and IgG were removed according to the manu-
facturer’s recommendation. The samples were then
desalted and lyophilized. The protein concentration was
determined according to Bradford [10].
2-DE analysis
The lyophilized proteins were dissolved in 0.20 ml urea
sample solution according to Görg [11]. 2-DE was per-
formed in a horizontal 2-DE setup (IPGphore and Multi-
phore from GE Healthcare), as described in detail
previously [12] and essentially according to Görg [11].
The samples (containing 50 μg protein for analytical gels
and 900 μg for preparative gels) were applied by in-gel re-
hydration (according to the manufacturer’s instructions)
Table 1 Musculoskeletal symptoms among farmers and
referents included in this study
Musculoskeletal symptoms Farmers Referents p-value
N = 13 N = 11
Neck and shoulder pain 9 6 ns
Hands and forearms(numbness) 4 4 ns
Hands and forearms(nocturnal pain) 1 2 ns
Low back pain 6 3 ns
Ischialgia 5 1 ns
Hips problems 10 5 ns
Groin-thigh pain 4 3 ns
Knee joint problems 8 2 ns
All symptoms 13 5 0.007
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for 12 h using low voltage (30 V) in pH 4–7 IPGs. The
proteins were then focused for up to 32 000 Vhs at a max-
imum voltage of 8000 V. IPGs were either used immedi-
ately for second dimensional analysis, or stored at −70 °C
until analyzed. The second dimension (SDS-PAGE) was
carried out by transferring the proteins to gradient gels
cast on GelBond PAG film (0.5/180/245 mm, 11–18%T,
1.5%C, 33–0 % glycerol) running at 30 mA and up to
1000 V for about 5 h. In analytical gels, separated proteins
were detected by silver staining according to Schevchenko
as described previously [12]. The preparative gels, for MS
analysis, were fluorescently stained with SYPRO Ruby
[12]. All staining and washing steps were performed with
continuous gentle agitation. The protein patterns were an-
alyzed as digitized images, using a CCD camera in com-
bination with a computerized imaging 12-bit system
designed for evaluation of 2-DE patterns. The amount of
protein in a spot was assessed as background corrected
optical density, integrated over all pixels in the spot and
expressed as integrated optical density (IOD). In order to
correct for differences in total silver stain intensity be-
tween different 2-DE images, the amounts of the com-
pared protein spots were quantified as optical density for
individual spot per total protein intensity of all spots in
the same gel. Thereby ppm-values (parts per million) for
all proteins were generated that were evaluated for differ-
ences between the groups.
Protein identification
Protein spots were excised using a homemade spot
picker. The picked protein spots were digested with
trypsin (Promega/SDS Biosciences, Falkenberg, Sweden)
as described previously [13]. The trypsinated peptides
were applied to mass spectrometry for protein identifica-
tion. The dried tryptic samples from fluorescently
stained proteins were dissolved in 6 μl of 0.1 % formic
acid. Peptides were analyzed using an on-line nano-flow
HPLC system (EASY-nLC; Proxeon, Bruker Daltonics)
in conjugation with the mass spectrometer HCTultra
PTM Discovery System (Bruker Daltonics) as previously
described [13]. LC-MS/MS spectra were processed by
Bruker Daltonics DataAnalysis 3.4 (Bruker Daltonics,
Bremen, Germany) and resulting MS/MS data were
searched in NCBInr and Swiss-Prot database on MAS-
COT server: www.matrixscience.com Database search
parameters were set as follows: the enzyme trypsin was
used; up to one missed cleavage was allowed; fixed
modification included were carbamidomethylation of
cysteine and oxidation of methionine; mass tolerance for
MS precursor ion was 0.8 Da and for MS/MS fragment
ion was 0.6 Da; and charge states were varied. Criteria
for identification of a protein were at least 3 peptides of
the protein should be identified with a MASCOT score
over 25 and an expectation value <1. The mass list
generated from the major peaks of the MALDI spectra
was submitted to a database search (NCBI or SWISS-
PROT) using MS-FIT search engines. Restrictions were
placed on species (Human), mass tolerance (50 ppm),
maximum missed cleavages by trypsin (up to 1) and
cysteine modification by carbamidomethylation.
Statistical analysis
Non-parametric Mann-Whitney U test was used as stat-
istical method to calculate significant differences be-
tween groups. A p < 0.05 was considered statistically
significant. All results are given as mean ± standard devi-
ation. IBM SPSS Statistics 20 was used as statistical
software.
Results
2-DE analysis and mass spectrometry
To determine proper 2DE conditions for the analysis to
be made, plasma proteins were separated in the pI
ranges 3–10 and 4–7 (first dimension) followed by SDS-
PAGE (second dimension). As illustrated in Fig. 1, most
of the spots detected in pI range 3–10 were also de-
tected in the pI range 4–7 (about 90 %). The marked
areas in Fig. 1 illustrate the good resolving power when
using IPGs in pI range 4–7 compared to 3–10. A few
proteins (Fig. 1a, dashed squares9 with pI outside the 4–
7 range were lost. Due to the good separation in the pI
range 4–7 we decided to analyze all samples using IPGs
4–7. Mapping of the plasma proteome in the pI range
4–7 was performed by mass spectrometry. Seventy five
spots could be identified (Table 2, Fig. 2). According to
the accession number these identified protein spots rep-
resent 20 different proteins. Several of the identified pro-
teins were expressed as different isoforms due to post-
translational modifications such as glycosylation and
phosphorylation.
Protein changes in farmers with MSD compared to rural
referents
More than 200 protein spots were detected in all sam-
ples. To investigate possible differences in the plasma
proteomes of farmers with MSD and rural referents,
protein spots present in at least 50 % of the gels in either
group were matched, quantified for intensity, and com-
pared between the groups. Proteins whose concentra-
tions were statistically different in the two groups were
then identified using mass spectrometry. As shown in
Table 3, the levels of leucine-rich alpha-2-glycoprotein,
haptoglobin, complement factor B, serotransferrin, one
isoform of kininogen (spot1507), one isoform of alpha-1-
antitrypsin (spot 2404), and two isoforms of hemopexin
(spots 6603 and 7602) were higher in farmers with MSD
than in rural referents. On the other hand, the levels of
alpha-2-HS-glycoprotein, alpha-1B-glycoprotein, vitamin
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D- binding protein, apolipoprotein A1, antithrombin, one
isoform of kininogen (spot 2607), and one isoform of
alpha-1-antitrypsin (spot 3802) were lower (Table 2). Fig-
ure 3 pinpoints the statistically differing proteins on a
2DE gel, while Fig. 4 illustrates how the different isoforms
of kininogen, alpha-1-antitrypsin, and hemopexin were
quantitatively expressed in farmers with MSD and refer-
ents, respectively.
Discussion
Using 2-DE and mass spectrometry proteomic tech-
niques, we were able to identify 15 proteins that were
present differently in the plasma of farmers with MSD
and their matched rural referents. Several of the proteins
with plasma levels higher among farmers than among
referents are well known as mediators or indicators of
inflammation. For example, complement factor B is es-
sential for complement activation via the alternate path-
way and so plays an important role in inflammatory
conditions such as arthritis [14–16] and muscle inflam-
mation [17]. Haptoglobin is established as an
inflammation-inducible plasma protein [18] that exerts a
regulatory activity on immune cell responses and host
immunity [19]. Accordingly, haptoglobin was found to
be a monocyte chemoattractant whose chemotactic po-
tential was mediated, at least in part, by its interaction
with chemokine (C-C motif ) receptor 2 [20]. Recently,
Park and co-workers demonstrated that the C-terminal
haptoglobin fragment is generated by plasmin in local
inflammatory environments, suggesting that this frag-
ment might be applied as a novel biomarker for the
diagnosis and prognosis of inflammatory joint diseases
such as rheumatoid arthritis [21]. Hemopexin belongs to
the acute phase reactants, the synthesis of which is in-
duced after inflammation. Aside from a systemic role in
preventing heme-mediated oxidative stress, hemopexin
might act as a local antioxidant at sites of injury and so
play a role in inflammation [22].
Analogously, some of the proteins with plasma levels
lower among the farmers than among the referents
(Table 3) are known to have anti-inflammatory proper-
ties and actions. Thus, antitrombin III has been shown
to inhibit cytokine and tissue factor production in endo-
thelial cells [23], attenuate CD11b/CD18 expression in
activated neutrophils and monocytes [24], suppress
granule secretion in activated platelets [25], prevent
apoptosis of hepatocytes [26, 27], and improve
endotoxin-induced acute lung injury in rats [28]. Alpha-
2-HS-glycoprotein a multifunctional molecule that may
serve as an inhibitor of systemic inflammation in mice
[29] and humans [30, 31]; notably, its serum levels were
significantly decreased in patients with RA [32, 33].
Vitamin D-binding protein (VDBP) is primarily known
as a transport protein but was found to be down-
regulated in serum of experimental animals with sys-
temic inflammation [34] and patients with sepsis [35,
36]. Moreover, Oh and coworkers recently found this
protein to be down-regulated in serum of patients with
carpal tunnel syndrome [37], a condition causing pain,
impairment, and disability. The molecular mechanisms
connecting inflammation with decreased VDBP are not
clear, but because VDBP is a precursor for macrophage
activating factor (MAF) it may be speculated that the de-
creased levels reflect increased formation of MAF and
ensuing activation of macrophages [38] and neutrophils
[39] at sites of inflammation. Alternatively, MAF may
function positively by causing death of the macrophages
when activated macrophages are no longer needed at the
site of inflammation [40] Clearly, much further investi-
gation is needed to elucidate why farmers with MSD ap-
pear to have decreased serum levels of VDBP.
One of the most important aspects of using 2DE is the
capability of resolving many post-translationally modified
Fig. 1 Comparison between plasma protein separation in pI range of 3–10 (a) and 4–7 (b). The marked areas are some example of the improved
resolution using IPGs 4–7
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Table 2 Identified proteins in plasma by nLC-MS/MS
Spot Nr Protein SwissProt Mw/pI Score Sequence coverage [%] Nr of unique peptides
1 Alpha-1-antitrypsin P01009 46878 / 5.37 194 21 7
2 Alpha-1-antitrypsin 474 33 12
3 Alpha-1-antitrypsin 382 32 15
4 Complement factor B P00751 86847 / 6.67 225 12 10
5 Complement factor B 266 16 12
6 Complement factor B 339 15 15
7 Complement factor B 252 15 14
8 Alpha-1B-Glycoprotein P04217 54790 / 5.56 51 1 6
9 Alpha-1B-Glycoprotein 108 7 3
10 Alpha-1B-Glycoprotein 142 12 5
11 Serotransferrin P02787 79294 / 6.81 414 19 13
12 Serotransferrin 988 52 31
13 Serotransferrin 889 42 28
14 Serotransferrin 1107 49 31
15 Serotransferrin 1078 49 31
16 N-acetylmuramoyl-L-alanine amidase Q96PD5 62748 / 7.25 31 1 1
17 N-acetylmuramoyl-L-alanine amidase 67 3 2
18 N-acetylmuramoyl-L-alanine amidase 98 3 1
19 Hemopexin P02790 52385 / 6.55 212 14 6
20 Hemopexin 306 23 11
21 Hemopexin 314 26 12
22 Hemopexin 329 25 11
23 Hemopexin 298 15 10
24 Hemopexin 277 20 9
25 Kininogen P01042 72996 / 6.34 321 11 6
26 Kininogen 308 9 5
27 Kininogen 203 10 6
28 Hemopexin P02790 52385 / 6.55 266 20 8
29 Hemopexin 49 2 1
30 Beta-2-Glycoprotein 1 P02749 39584 / 8.34 172 16 5
31 Kininogen P01042 72996 / 6.34 127 8 4
32 Kininogen 275 17 8
33 Kininogen 236 13 8
34 Kininogen 254 15 8
35 Alpha-1-antitrypsin P01009 46878 / 5.37 962 45 17
36 Alpha-1-antitrypsin 730 43 18
37 Alpha-1-antitrypsin 1009 47 17
38 Alpha-1-antitrypsin 509 42 16
39 Vitamin D-binding protein P02774 54526 / 5.40 476 36 16
40 Alpha-1-antitrypsin P01009 46878 / 5.37 620 51 19
41 Vitamin D-binding protein P02774 54526 / 5.40 381 25 11
42 Antithrombin III P01008 53025 / 6.32 333 25 10
43 Leucine-rich alpha-2-glycoprotein P02750 38382 / 6.45 224 17 6
44 Leucine-rich alpha-2-glycoprotein 131 14 5
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proteins that may appear as isoforms. We identified two
isoforms of hemopexin that both were present in higher
amounts in the plasma of farmers (Table 3, Fig. 4). More-
over, we identified two proteins (kininogen and alpha-1-
antitrypsin) that were present differently in the plasma of
farmers and referents depending on isoform, i.e., one iso-
form was present in a higher amount in the farmer group
vs the referent group, and another isoform was present in a
higher amount in the referent group vs the farmer group
(Table 3, Fig. 4). While we are unable to conclusively ex-
plain these findings, it can be noted that these proteins, too,
are being associated with inflammatory processes and dis-
eases. Thus, kininogen is the precursor of bradykinin, a
well-known mediator of inflammation and pain [41–43]
that plays a crucial role in rheumatoid arthritis [44]. Alpha-
1-antitrypsin can exert anti-inflammatory activity in many
tissues and organs including the musculoskeletal system;
notably, low levels of alpha-1-antitrypsin have been sug-
gested to contribute to the development of rheumatoid
arthritis [45] and MSD [46]. Yet, changes in isoforms of ki-
ninogen, alpha-1-antitrypsin, and hemopexin have not pre-
viously been reported. We do not know the exact chemical
nature of the isoforms found in our study and are currently
attempting to ascertain post-translational modifications.
Characterization of the chemical nature of these protein
isoforms, determination of the tissue(s) that produce them,
and the relationship between these isoforms and other
interacting proteins—all of these, as they relate to the
causal events of MSD, may lead to a further understanding
of the progression to MSD in farmers.
Table 2 Identified proteins in plasma by nLC-MS/MS (Continued)
45 Leucine-rich alpha-2-glycoprotein 134 17 4
46 Haptoglobin P00738 45861 / 6.13 302 21 9
47 Haptoglobin 273 26 10
48 Haptoglobin 296 27 10
49 Zinc-Alpha-2-glycoprotein P25311 34465 / 5.71 223 17 7
50 Zinc-Alpha-2-glycoprotein 226 24 8
51 Clusterin P10909 53031 / 5.89 219 17 7
52 Clusterin 203 14 7
53 Clusterin 331 22 9
54 ApoA1 P02647 30759 / 5.56 419 44 13
55 ApoA1 775 62 16
56 ApoA1 4287 53 14
57 ApoA1 850 48 8
58 Haptoglobin P00738 45861/6.13 2
59 Haptoglobin 2
60 Transthyretin P02766 15887/ 5.5 4357 69.4 11
61 Transthyretin 8483 64.6 7
62 ApoCIII P02656 8800/4.7 65 4
63 ApoCIII 65 4
64 ApoAII P02652 9300/6.5 56 5
65 ApoCII P02655 8900/4.7 96 6
66 Alpha-2-HS-Glycoprotein P02765 39325/5,4 60245 22.9 9
67 Alpha-2-HS-Glycoprotein 60245 20.4 8
68 Alpha-2-HS-Glycoprotein 60245 20.4 8
69 Alpha-2-HS-Glycoprotein 60245 20.4 8
70 Haptoglobin P00738 45861/6.13 14986 24.1 11
71 Haptoglobin 12798 23.2 8
72 Haptoglobin 12728 21.9 8
73 Haptoglobin 60393 28.3 11
74 Haptoglobin 12798 23.2 8
75 Haptoglobin 12728 21.9 8
The spot numbers refer to marked protein spots in Fig. 1
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While the levels of leucine-rich alpha-2- glycoprotein
were higher in the farmer group, the levels of alpha-1B-
glycoprotein were higher in the referent group (Table 3).
Whether these proteins, too, are involved in inflamma-
tion or not remains unclear. The physiological role of
leucine-rich alpha-2- glycoprotein is not known;
however, its 33 % sequence homology with a beta-type
phospholipase A2 inhibitor [47] suggests the possibility
that it might modulate inflammation and pain through
inhibition of phospholipase A2 activity. As to alpha-1B-
glycoprotein, decreased plasma levels of this protein were
found in patients with rheumatoid arthritis [32] but little
Fig. 2 A typical 2DE protein pattern of human plasma in pI range of 4–7. The marked spots refer to identified proteins in Table 1
Table 3 Proteins that were present differently in the plasma of farmers with MSD and their matched rural referents (RR)
Spot Protein MSD vs RR Accession number OD (MSD) Mean ± (SD) × 103 OD (RR) Mean ± (SD) × 103 p-value
311 Alpha-2-HS-Glycoprotein ↓ P02765 4.768 (3.556) 7.720 (2.386) 0.046
1318 Leucine-rich alpha glycoprotein ↑ P02750 4.587 (3.355) 2.081 (1.285) 0.04
1507 Kininogen ↑ P01042 5.288 (2.631) 3.425 (1.684) 0.049
2404 Alpha1-anti trypsin ↑ P01009 12.938 (7.270) 7.799 (6.398) 0.04
2607 Kininogen ↓ P01042 6.885 (3.786) 10.114 (2.964) 0.03
3802 Alpha1-anti trypsin ↓ P01009 0.884 (0.840) 3.117 (3.168) 0.019
4806 Alpha-1B-glycoprotein ↓ P04217 4.677 (2.359) 6.487 (1.138) 0.01
5507 Vitamin D binding protein ↓ P02774 5.506 (2.400) 8.585 (2.693) 0.03
6007 Apolipoprotein A1 ↓ P02647 3.765 (3.513) 6.838 (2.857) 0.010
6502 Antithrombin III ↓ P01008 1.940 (1.750) 5.128 (2.950) 0.005
6603 Hemopexin ↑ P02790 7.613 (5.647) 2.377 (2.225) 0.019
7101 Haptoglobin ↑ P00738 5.455 (1.552) 3.573 (1.382) 0.008
7602 Hemopexin ↑ P02790 10.729 (3.657) 4.121 (2.744) 0.000
8707 Complement factor B ↑ P02790 2.468 (2.920) 1.226 (2.029) 0.022
8811 Serotransferrin ↑ P02787 8.633 (3.460) 5.355 (2.047) 0.010
The spot numbers refer to the marked spots in Fig. 3
Arrow up (↑) indicates up-regulated and arrow down (↓) down-regulated proteins in farmers with MSD compared to RR
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Fig. 3 Significantly changed proteins in farmers with musculoskeletal disorders compared to rural referents
Fig. 4 Quantitative data for protein isoforms that significantly (p < 0.05) changed in farmers with musculoskeletal disorders compared to rural
referents. The blue marked spots are the different isoforms and the red circle is the significantly changed protein
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is known about the function of this protein and the
biological relevance of this finding is therefore uncer-
tain. The reason why serotransferrin (the major iron-
transporting plasma protein) was higher in the farmer
group is also uncertain; interestingly, its plasma levels
were affected in an experimental model of neuro-
pathic pain [48]. Apolipoprotein A1 (ApoA1) has been
shown to have anti-inflammatory properties and to
reduce atherosclerosis [49]; one would expect, there-
fore, that farmers (who are at lower risk for cardio-
vascular disease than the general population) had
higher (rather than lower) apoA1 than referents. On
the other hand, the level of apoA1 in lipoproteins has
been found to correlate positively with PCYOX1 [50],
an enzyme which generates H2O2 and so probably
plays a role in atherogenesis [51]. Based on this find-
ing, Sun and coworkers suggested that high apoA1
content might be associated with increased risk of
cardiovascular disease [50]. Further investigation is re-
quired to clarify the reason why farmers with MSD
appear to have decreased serum levels of apo A1.
Although we were able to identify a protein profile
that differentiates farmers with MSD from referents
using proteomic techniques, the methods used in
this study may pose some limitations. We used iso-
electric points and molecular weight of the proteins
to separate the proteins onto a two-dimensional gel.
We were limited therefore to investigating proteins
within a certain range of isoelectric points and mo-
lecular weight, thereby excluding several proteins
that may be potential candidates for biomarkers of
MSD in farmers. Furthermore, we used a depletion
column to remove the high abundant proteins (albu-
min and IgG) before analysis these proteins give
substantial background to the 2DE profiles and make
analysis difficult [5]; it is not impossible that this
procedure might have eliminated some other candi-
dates. As to the protein resolution, we have little
reason to believe that the methods used have posed
further limitations; rather, an advantage of 2DE com-
pared to other separation methods is the quality of
protein resolution [52] as shown by the capability of
resolving many post-translationally modified proteins
that may appear as isoforms. Identity of each protein
spot was determined by mass spectrometry, which is
the method of choice for accurate probability based
protein identification. Moreover, it is unlikely that
the results are flawed by unacceptable analytical er-
rors; densitometric analyses combined with silver
staining of proteins are highly quantitative and a me-
dian coefficient of variation of approximately 8 %
has been reported using similar parameters as used
in our procedure (i.e., fluorescent staining, PDQuest
software) [53].
Conclusions
In conclusion, we have identified a number of proteins
that are present differently in the plasma of farmers with
MSD and their rural referents. Many of these proteins
are known to be mediators or indicators of inflamma-
tion, supporting the hypothesis that farmers with MSD
may be subject to a more systemic inflammation. The
implication of these findings is worth considering. First,
it is possible that the identified proteins may give clues
to the biochemical changes occurring during the devel-
opment and progression of MSD in farmers and so con-
tribute to a deeper understanding of the pathogenetic
mechanisms behind MSD and related symptoms/find-
ings in other organ systems. Second, one or several or a
combination of the identified proteins might possibly be
used as a biomarker(s) of MSD in farmers. Much further
investigation is therefore warranted, including compari-
sons of farmers with and without MSD and referents
with and without MSD to elucidate how MSD protein
picture relates to exposure. Third, if it turns out that a
plasma biomarker(s) appears early during the develop-
ment of MSD in farmers, this biomarker(s) might even-
tually be used to identify farmers who are at greater risk
and to prevent progression of the disease process.
This study provides novel information about the
biological mechanisms behind MSD in farmers and
makes it possible to explain the link between health
outcomes and the work environment. We identify
biomarkers of systemic inflammation that contribute
to better understanding of the pathophysiological
processes involved in MSD. Although farmers are a
relatively small occupational group in Sweden today,
the identification of the causes of work-related MSD
in this group may be a valuable tool for understand-
ing of similar phenomenon in other groups. The re-
sults of this study thus may contribute to a better
understanding of how problems in the musculoskel-
etal system generally arise.
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